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Background: When population-based databases are unavailable, nationwide
assessments of the disease burden of multiple sclerosis (MS) resort to clinical,
administrative or convenience-sampled data sources, which may produce results of
limited external validity. Our aim was to develop a framework for estimating measures of
occurrence of chronic diseases, and more broadly disease burden, that mitigate these
limitations and to apply this framework to estimate the prevalence of multiple sclerosis
(MS) in Switzerland.
Methods: We developed a 7-step framework which implements the combination
of several data sources together with a resampling and critical appraisal approach.
The framework was applied to estimate the MS prevalence for 2016 in Switzerland,
for which four distinct data sources (Swiss MS registry, Swiss national MS treatment
registry, MediService database, and Swiss MS cohort study) were combined. Results
were reviewed by disease experts and compared to earlier Swiss estimates and current
prevalence estimates from other countries.
Results: We estimate that in the year 2016 between 14,650 and 15,700 persons with
MS have been living in Switzerland, yielding a period prevalence of 174–187/100,000
inhabitants. Compared to the last estimate in 1986, we detected a substantial increase
of MS diagnoses which coincides with a higher number of diagnoses in women below
the age of 65.
Conclusions: Internationally, Switzerland is a high-prevalence country for MS, although
estimates were somewhat lower than recent evaluations of Northern European countries.
In addition, we corroborate previous reports that the prevalence increase coincides with
a higher number of MS diagnoses among women. The proposed framework has wide
applicability and the potential to place estimates of disease occurrence and burden with
imperfect data availability on more solid grounds.
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INTRODUCTION
In the field of Multiple Sclerosis (MS), studies on the prevalence
of MS have a long history, and follow a multitude of approaches.
In Northern-European countries, for example Denmark, the
existence of national health care and disease databases with very
high population coverage allow a direct estimation from these
data (1). By contrast, in settings without mandatory reporting of
new MS diagnoses, some studies have relied on regional, clinic-
based estimates (e.g., based on new and existing diagnoses),
followed by nation-wide extrapolation (2, 3). Following the
second approach, the point prevalence of MS in Switzerland was
last thoroughly estimated by Beer and Kesselring to be around
100/100,000 inhabitants (4).
In Switzerland and many other countries, accurate estimation
of measures of disease occurrence and burden is a challenging
task for several reasons. First, although not considered a
rare disease, MS is still not frequent enough to be measured
efficiently through random sampling of the general population.
This is further complicated by the universal challenges of a
sound random sampling (5, 6). Second, changing diagnostic
criteria, reclassification of syndromes such as Neuromyelitis
Optica Spectrum Disorders (NMOSD) as not being MS and
the availability of treatment options altering the disease course
[disease-modifying treatments (DMT)] have impacted the
definition of MS and hence also epidemiological measures (7–
10). Therefore, the comparison of earlier estimations with newer
assessments needs to take these changes in MS case definition
into account. Third, epidemiological assessments relying on
clinical or convenience samples are not always externally valid
and could therefore lead to incorrect extrapolations. Against this
background, a detailed understanding of inclusion- and selection
mechanisms of the analytic databases, as well as of the factors
“driving” an outcome of interest is crucial (6, 11, 12).
Despite the emerging literature on statistical methods for
assessing and improving external validity, there is very limited
guidance for more practically oriented research to assess the
representativeness of burden of disease parameters derived from
non-randomly sampled (clinical or administrative) databases.
Moreover, there has—to our knowledge—never been an attempt
for a more unified approach to estimate burden of disease
parameters for MS from non- population-based databases. The
present study therefore has two aims. First, it aims to provide
an update of the prevalence of MS in Switzerland. Second, it
will do so by developing a framework approach for comparing
and combining data from different datasets and for assessing the
external validity.
METHODS
Available Datasets
The Swiss Multiple Sclerosis Registry (SMSR) is a patient-
centered registry that prospectively enrolls and follows adult
persons with MS (PwMS) in Switzerland (n= 1,911 as of Feb 11,
2019). The Swiss MS registry is an observational study based on
self-reported data which is supplemented with detailed clinical
data for a subpopulation of ∼15%. The registry has specifically
been structured to also include PwMS that are usually less likely
to participate in clinical studies, for example, people with a
new diagnosis, severe impairments or living in areas far from
MS centers (13, 14). The Swiss MS registry covers the full
spectrum of the Swiss MS population with potential slight under
representations in very young and older age groups of PwMS. The
Swiss MS registry study was approved by the ethics committee
of the canton of Zurich (PB-2016-00894) and written informed
consent was obtained from all participants (13). All data were
pseudonymised prior to analysis.
This study also had access to the Swiss national MS treatment
registry, administered by the Swiss association for joint tasks of
health insurances (SVK), which is an administrative database
in Switzerland and is used for the reimbursement process of
disease-modifying therapies (DMT) for MS for certain insurance
companies (15). Due to the mandatory health insurance system
in Switzerland with very comprehensive coverage of essential
treatments, DMTs are reimbursed fully if drugs are utilized
according to formal approval criteria. Therefore, the access to
DMT and neurological care in general is unrestricted (15, 16). In
consequence, the Swiss national MS treatment registry delivers
a good estimate of DMT users in the insurances covered by
the Swiss association for joint tasks of health insurances. These
insurances had a market share of 67% in 2016, the index year
of the study. The database contains anonymized, individual-level
DMT reimbursement information which consist for example
of the disease course, type of drug or date of diagnosis, filled
in by neurologists. The ethics committee of North-West and
Central Switzerland (EKNZ UBE Req-2019-00470) has provided
a confirmation that the SVK data do not fall under the Swiss
Human Research law. The Clinical Trial Unit at the University
Hospital of Basel is responsible for the data (17).
MediService is a company in Switzerland that offers a service
to handle the entire DMT process, from the prescription to the
delivery of DMT, including the payment with the insurance as
well as, if applicable, the reimbursement approval by the Swiss
association for joint tasks of health insurances (therefore allowing
to compare patients who are included in the Swiss national MS
treatment registry databases and those who are not). For this
study, we used aggregated data of the year 2016.
For validation purposes, we further reviewed data from
the Swiss Multiple Sclerosis Cohort study (SMSC). The Swiss
MS cohort study is a prospective, clinical cohort of PwMS in
Switzerland, which are included at 7 Swiss university hospital
settings, and are regularly surveyed. The data collection includes
information about disease characteristics, MRI data and body
fluid sampling. This study is prospectively following 1,200 PwMS,
with a median follow-up duration of 3 years at the end of
2016 (18). For this study, aggregated data until the end of 2016
was used.
Framework for Estimating the Burden of
Chronic Diseases
The general outline of the estimation framework is shown in
Figure 1. It consists of 7 steps. Limitations in the individual
steps, for example non-applicability or limited credibility, do
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FIGURE 1 | General outline of the 7 steps of the framework to estimate the burden of chronic diseases.
not prohibit the use of the framework. However, the limitations
should be considered when defining the estimation uncertainty
and clearly highlighted in the discussion. For the present use
case, the estimation of MS prevalence in Switzerland, the core
estimation process is based on the benchmark-multiplier method
discussed by Bollaerts et al. (19). For the seven steps presented
below, we will, in each step, first introduce the goal and generic
idea and then describe its specific implementation for our
use case.
Step 1 – Define Quantity of Interest
The quantity of interest, often the prevalence, needs to be defined
precisely. This definition consists of, among other things, the
case definition, the exact definition, and the size of the target
population (i.e., to which population the estimate should apply)
and the index time.
Prevalence of MS
The quantity of interest in our study was the period prevalence of
persons with clinically-definite MS in Switzerland in the index
year 2016. The target population was the Swiss population in
2016 which consisted of∼8,420,000 (20).
Step 2 – Define Subgroups and Characteristics
Step 2 consists of the definition of specific disease population
subgroup(s) and key disease characteristics. Specific in this
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context means that the members of a subgroup can be identified
with no or very little misclassification and that the subgroup
is reasonably large (>10% of population). Furthermore, the
subgroup(s) should be chosen in a way that reliable information
on the subgroup size are available. In case more than one
subgroup is of interest, the subgroups have to be mutually
exclusive. Key disease characteristics are those that play a major
role in the characterization of the disease. They can most easily
be found by reviewing study population descriptions of previous
disease-specific publications.
Prevalence of MS
In our use-case we defined our subgroup to be the PwMS
taking a DMT in the last 12 months, because we were
already aware of the existence of a dataset covering this
group. Key disease characteristics were the disease subtype
and duration, the treatment status and type, the disability and
demographic information.
Step 3 – Select and Review Datasets
Step 3 includes the search for and review of available disease-
specific datasets and their assessment with regard to suitability
and quality. The minimal number of datasets depends on the
quantity of interest as well as the chosen estimation method,
but in general more datasets are preferable. For example, for
the benchmark-multiplier method, at least two datasets are
needed, one containing absolute group-sizes (benchmark), and
another one that is population-based and reflects the target
population (multiplier) (19). The quality of the datasets should
be assessed individually by looking at the specific population
characteristics, patient selection effects, and potential issues with
external validity. Furthermore, the inclusion of the predefined
subgroups from step 2 datasets should be verified in the different
datasets and compared with respect to key disease characteristics.
Prevalence of MS
The following search strategy was applied to our use case. First,
we screened the literature forMS studies in Switzerland, as well as
the references leading to other studies. Moreover, disease-experts
were contacted to learn about existing data sources. This process
led to the identification of four main data sources for our study.
For the benchmark dataset with the absolute group-sizes, the
Swiss national MS treatment registry dataset was identified as a
suitable database. In addition, the Swiss MS registry was selected
as the most suitable dataset, reflecting the target population,
the multiplier (19). In addition to these, the MediService and
the Swiss MS cohort study data were reviewed and obtained
for later use. We reviewed the datasets and compared the
coinciding subgroups regarding key disease characteristics and
found generally good correspondence (cf. results section).
Step 4 – Create a Model Framework
This step involves the model specification and the determination
of the estimation formulas which highly depend on the quantity
of interest. Any assumptions regarding the data, the definitions,
and the estimation process should be clearly outlined and
assessed in the specified datasets. Furthermore, the existence
of all predefined parameters for the estimation needs to be
assessed (that is, parameters with assumed or literature-derived
values owing to a lack of data). Moreover, by use of additional
datasets from step 3, the main databases for estimation should
be reviewed regarding possible distributional differences of
key disease characteristics. This step is intended to increase
the credibility of the data sources and to mitigate observed
distributional differences in later analysis steps. In the case
of large disagreements between the different data sources, the
uncertainty should be reasonably considered in the estimation
in step 5. The findings and possible limitations derived from
this step should be adequately reflected and addressed in the
Discussion section of research reports.
Prevalence of MS
The basic approach was the benchmark-multiplier method. This
method operates by dividing the group size of the specified
subgroup (Nˆx), so the benchmark, by its percentage of the entire
population (pˆi), themultiplier, as displayed in Formula (1),
Prevalence =
Nˆx
pˆi
. (1)
However, as discussed by Bollaerts et al. (19) this
estimator is biased and therefore we used the suggested
bias-corrected estimator,
Prevalence =
Nˆx
pˆi
−
1
n
∗Nˆx∗
(
1
pˆi
− 1
)
, (2)
with n being the sample size of the multiplier (19). In particular,
a subtraction term is included in the equation, which depends
on the sample size of the benchmark (Nˆx), inversely on the
sample size of the multiplier dataset ( 1n ) and on the population
percentage that is covered by themultiplier ( 1
pˆi
− 1).
The prevalence per 100,000 persons at risk was estimated
as follows:
Prevalence per 100′000 =
Prevalence
Population at risk
∗100
′
000. (3)
The key assumptions of the benchmark-multipliermethod consist
of the benchmark covering the subgroup exhaustively, the
multiplier being representative of the target population and the
subgroup definition of the benchmark exactly coinciding with the
corresponding subgroup of themultiplier (19).
The parameters for the estimation with the benchmark-
multiplier method were available from an augmented Swiss
national MS treatment registry dataset and the Swiss MS registry
database. The augmented Swiss national MS treatment registry
dataset relies on the Swiss national MS treatment registry data,
which was complemented by additional (pseudo-) records so
as to reflect also the population of PwMS receiving DMT,
whose reimbursement applications are not processed by the
Swiss association for joint tasks of health insurances. These
pseudo-records were constructed on the basis of the MediService
database, which includes all types of DMT prescriptions (i.e.,
those submitted to the Swiss association for joint tasks of
health insurances and others that are directly submitted to
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individual insurers). The exact details of this step, which balanced
misrepresentations in the Swiss national MS treatment registry,
are shown in the Supplementary Material.
In addition, the Swiss MS registry database was compared
to aggregated data from the Swiss MS cohort study (which are
not directly used in the benchmark-multiplier estimation) in
order to ascertain approximate representativeness of the Swiss
MS population and the DMT usage patterns.
Step 5 – Estimate Quantity of Interest
In Step 5, the calculations on the basis of Step 4 are executed.
For all random parameters, a probability distribution of plausible
values reflecting the estimation uncertainty needs to be defined.
The distributions and the uncertainty are determined based
on the observed variability of key parameters across the
different study databases, as well as based on information
from the literature. For the calculation process, values for
random parameters are repeatedly drawn from the pre-defined
distributions and the estimation process is repeated a large
number of times. Main outcome results are recorded. The final
estimation result is a distribution of main outcome parameters,
which reflects the pre-defined assumptions (also regarding
literature-based parameters), as well as the uncertainty stemming
from distributional differences across the different databases used
in the analyses.
Prevalence of MS
The review process in steps 3 and 4 indicated uncertainties in
two main parameters, which were addressed in the modeling
study by defining conservative probability distributions to draw
values from. These parameters were (1) the group size of the
persons using DMT in 2016 (benchmark) and (2) the share
of the entire PwMS population this group reflects (i.e., the
multiplier). Subsequently, the parameters were then drawn from
the distributions, and the estimation was executed according to
Formulas (2) and (3). This process was repeated 100,000 times.
Estimations of the absolute number of PwMS were performed
separately for 5-years strata of disease duration, which were then
collapsed into a single parameter (overall number of PwMS).
Step 6—Validate Results
In step 6, the estimated distributions as well as the modeling
assumptions need to be subject to critical review. If available,
the results should be validated using other databases that were
not included in the estimation process and should ideally stem
from the same country and the same period. If unavailable, other
databases may be used, but comparability of key assumptions and
subgroups must be ascertained.
Prevalence of MS
We carefully reviewed the assumptions of our estimation and
the obtained distribution of the number of PwMS living in
Switzerland. Furthermore, we compared the age- and sex-specific
MS prevalence per 100,000 to the values of the estimation of Beer
and Kesselring in 1986 (4). Lastly, the MS prevalence per 100,000
of the UK, Sweden, Norway, Denmark, France and Germany
were set in context to our results (1, 21–26).
Step 7—Critically Appraise Results
The results are critically discussed with disease experts in the last
step. Whenever possible, these persons should not be directly
involved in the estimation to take a fresh view on the results.
In the case of disagreements, the assumptions as well as the
datasets should be carefully reviewed. Major concerns by the
expert should either be reflected in an improved estimation
process and/or highlighted as study limitations in the Discussion
section of the research report.
Prevalence of MS
As a control step, we defined subgroups based on disease course
and DMT usage pattern and determined their group sizes based
on occurrence frequencies in the Swiss MS registry. The period
prevalence distribution as well as the groups were then critically
discussed by the scientific committee of the Swiss MS registry
which consists of Swiss MS specialists. They were not directly
involved in the estimation.
Statistical Analysis
All statistical analyses were performed using R, version 3.5.3.
(27) (RRID:SCR_001905).
RESULTS
All datasets used for this study are summarized in Table 1.
Specifically, the comparison of the Swiss MS registry subgroup
using DMT and the Swiss national MS treatment registry,
Table 1 columns 2 and 3, as referred to in Step 3, shows
some differences. The Swiss MS registry has a higher share of
women (78.0 vs. 71.3%), fewer persons on first-line injectable
treatments (24.5 vs. 31.4%) and a higher share of persons with
a secondary-progressive MS (9.2 vs. 5.6%). The difference in the
regional distribution disappeared after the extrapolation in Step
5, Table 1 column 4.
The comparison of the Swiss national MS treatment registry
with theMediService data,Table 1 columns 3 and 5, showed good
agreement apart of fewer infusion therapies in the MediService
data (11.9 vs. 4.1%) and some regional differences.
The SwissMS registry compared to the SwissMS cohort study,
Table 1 columns 1 and 6, showed clear population differences,
for example regarding median age (Swiss MS registry: 48, Swiss
MS cohort study: 41), the treatment status (Swiss MS registry
current: 62.1%, Swiss MS cohort study current: 80.2%) and the
MS type (Swiss MS registry RRMS: 72.2%, Swiss MS cohort study
RRMS: 86.3%).
For the estimation, all necessary parameters were available
from either the augmented Swiss national MS treatment registry
(Nˆx = 9,503) or the SwissMS registry (pˆi = 62.1% and n= 1,567).
Regarding the assumptions, the Swiss national MS treatment
registry is not exhaustive, however, was extrapolated using
MediService data to the augmented Swiss national MS treatment
registry. The representativeness of the Swiss MS registry of the
target population was considered by the dataset comparisons
(Swiss national MS treatment registry and Swiss MS cohort
study). The coinciding subgroups condition was fulfilled (step 3).
Because the two key parameters for the estimation (Nˆx and
pˆi) were not known precisely, they were sampled from a
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TABLE 1 | Comparison of multiplier and benchmark datasets as well as external data.
Description
SMSR SMSR SVK SVK augmented Mediservice SMSC
All with CDMS DMT in last 12 months DMT in 2016 DMT in 2016 DMT in 2016 In care at MS centers
N 1,567 973 6,057 9,503 4,613 1,115
Female 73.6% 78.0% 71.3% 71.2% 71.0% 65.8%
Median age (IQR) 48 (38–56) 44 (36–52) 45 (36–53) 45 (36–53) – 41 (33–50)
Age Categories
19–49 55.5% 68.2% 63.6% 65.6% 63.7% –
50–64 34.5% 28.4% 30.5% 28.7% 30.2% –
65 and older 10.1% 3.4% 5.9% 5.7% 6.1% –
DMT status
% never received DMT 13.8% – – – – 7.2%
% ever exposed to DMT 24.1% – – – – 12.6%
% receiving DMT in last 12 mt 62.1% 100% 100% 100% 100% 80.2%
DMT type *
No treatment 37.9% – – – – 19.8%
Interferon/Glatiramer Acetate 15.2% 24.5% 31.4% 33.9% 38.8% 7.9%
Oral 37.1% 59.8% 56.8% 53.0% 57.1% 49.7%
Other infusion therapies 9.8% 15.7% 11.9% 13.0% 4.1% 21.1%
MS type **
Relapsing-remitting MS 72.2% 90.8% 94.4% 94.8% – 86.3%
Secondary-progressive MS 16.8% 9.2% 5.6% 5.2% – 5.3%
Primary-progressive MS 10.9% – – – – 4%
Disease duration from FS (IQR) 11 (6–19) 9 (5–16) 8.0 (3.6–14.2) 8.1 (3.8–14.2) – 10.0 (5.5–16.7)
Region
Lake Geneva region 11.5% 11.2% 8.3% 14.1% 7.7% –
Midlands 25.1% 24.9% 22.6% 24.6% 24.4% –
North-western Switzerland 16.6% 16.0% 18.9% 16.5% 19.1% –
Eastern Switzerland 14.1% 14.3% 17.1% 13.8% 17.7% –
Ticino 3.5% 3.5% 0.9% 3.0% 5.5% –
Central Switzerland 8.3% 8.4% 11.8% 9.5% 10% –
Zurich 20.9% 21.7% 20.4% 18.5% 15.7% –
Columns 1 and 2 display the population characteristics of the Swiss Multiple Sclerosis Registry in total (column 1) and the subsample which used DMT in the last 12 months (column 2).
Columns 3 and 4 display the information of the Swiss national MS treatment registry dataset as well as the augmented Swiss nation MS treatment registry dataset which represents the
entire population of persons with MS using a DMT in 2016. Column 4 displays the characteristics of the Mediservice dataset, which is an aggregated dataset that contains information
about persons with MS using the drug delivery and handling service of the MediService company. Column 5 shows aggregated data of the Swiss Multiple Sclerosis Cohort (SMSC)
study, a clinic based, longitudinal cohort in Switzerland in 2016. *1.5% have other DMTs. **4.1% have a CIS. CDMS, Clinically Definite Multiple Sclerosis; DMT, Disease-Modifying
therapies; FS, First Symptoms; IQR, Interquartile Range; MS, Multiple Sclerosis; SMSC, Swiss Multiple Sclerosis Cohort; SMSR, Swiss Multiple Sclerosis Registry; SVK, Swiss national
MS treatment registry.
uniform distribution for the analysis to account for this
uncertainty. The distribution width was defined to provide
a conservative range on the basis of observed information
and an additional margin reflecting the remaining uncertainty.
The empirical estimates of the group size of the subgroup
using DMT (Nˆx) mainly depended on the assumed Swiss
national MS treatment registry coverage of Swiss PwMS and
were derived from the MediService and the Swiss national MS
treatment registry datasets. The observed Swiss national MS
treatment registry coverage difference between the two databases
was 2% (Swiss national MS treatment registry reported: 67%,
MediService 65%). However, because the exact shares could
not undoubtedly be identified, we decided for a conservative
sampling distribution range of Nˆx +/- Nˆx∗0.05. For the
percentage of persons with MS who used a DMT (pˆi), the
confirmatory information consisted of Swiss MS registry data
and previously reported information of a Swiss burden and cost
of MS study by Calabrese et al. (28). The observed difference
in the percentage of persons receiving DMT between the two
databases was 1.4% (Swiss MS registry: 62.1%, Calabrese: 63.5%)
(28). However, because the Calabrese study did not work
with a prevalence sample and the disease course distribution
was likely shifted, we decided to include a conservative
range of pˆi +/- pˆi∗0.05.
The estimation resulted in a total number of 14,650–15,700
(95%-interval) PwMS living in Switzerland (period prevalence),
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FIGURE 2 | Distribution of the number of persons living with MS in
Switzerland. The y-axis depicts the percentage of the 100,000 samples in a
specific range based on the resampling approach. The 95% confidence
interval reaches from 14,650 to 15,700.
Figure 2. The prevalence per 100,000 ranged from 174.0/100,000
to 186.7/100,000 (95%-interval).
The comparison between the sex- and age-specific prevalence
per 100,000 inhabitants in 1986 and 2016 is shown in Figure 3. In
women until the age of 65 the prevalence increased by 150–300%.
The results were reviewed by an expert panel and approved
as sensible with the slight exception of potential disease course
shifts (mixture of secondary-progressive MS and primary-
progressive MS).
DISCUSSION
This study proposes an estimation framework for the disease
burden of chronic diseases and applied it successfully to
estimate the prevalence of multiple sclerosis in Switzerland. A
period prevalence between 14,650 and 15,700 (174.0/100,000–
186.7/100,000) in 2016 was estimated and judged as reasonable
by Swiss MS specialists. Compared to prior estimates from 1986,
the number ofMS diagnoses in women is higher, however, inmen
we did not detect a difference.
The newly obtained prevalence estimate of MS in Switzerland
is substantially higher than the last estimate by Beer and
Kesselring (4). The estimate is likely to be minimally larger still,
because the SMSR only includes adult PwMS but not children.
However, the expected number of persons with pediatric MS is
low (29).
The prevalence per 100,000 fits well in with recent European
estimates, which is reassuring as the Swiss population in 2016
has a similar age structure compared to the European standard
population (20, 30). For example, the prevalence per 100,000
inhabitants in the UK (2010: 203.4/100,000), Sweden (2008:
188.9/,100,000) and Norway (2013: 208/100,000) were slightly
higher (21–23). The estimates of Denmark (2005: 154.5/100,000)
and France (2012: 151.2/100,000) were marginally smaller (1, 24).
In contrast, the prevalence of the neighboring country Germany
(Bavaria 2015: 277/100,000, Germany 2010: 289/100,000) was
markedly higher (25, 26).
Furthermore, looking at the age- and sex-specific prevalences,
the increase observed in this study coincides with higher number
of diagnoses in women below the age of 65. This corresponds
well to the finding of Koch-Henriksen et al. that the incidence
of MS strongly increased in women, especially from 1980
on (31). This study, however, cannot disentangle the effect
of increased incidence compared to improved diagnoses and
increased awareness on the higher prevalence. The suggested
increase of the incidence of late-onset MS cannot be seen from
the Swiss data.
The potential causes of the observed increase in Switzerland
are difficult to disentangle but could be related to the factors
already discussed by Koch-Henriksen et al., namely a better and
earlier case ascertainment in recent years, increased cigarette
smoking, increased occurrence of obesity and fewer childbirths
(31). However, the temporal trends of these risk factors only
partially overlap with the observed age structure in this study,
thus leaving room for the impact of other, currently unknown
factors (32). In addition, the shift in demographics and increased
life expectancy between 1986 and 2016 is likely to have increased
the prevalence of MS.
Regarding the limitations, some short-comings on the data
side need to be mentioned. The comparison of the Swiss
MS registry subgroup with the Swiss national MS treatment
registry dataset showed differences regarding type of DMT
and the sex-ratio. Reasons for these differences might be the
underlying insurance population covered and the potential
underrepresentation of the Swiss MS registry in the tails of
the age distribution. However, we are convinced that these
factors have a minimal influence on the overall prevalence.
The difference in the distribution of disease courses (relapsing-
remitting MS vs. secondary-progressive MS) is likely to be
due to misclassification in the Swiss national MS treatment
registry database. Additionally, no single dataset is available for
external verification of the Swiss MS registry distributions and
as a consequence the estimation results. However, the observed
differences between the Swiss MS registry to the Swiss MS
cohort study validation dataset were expected and plausibly
explainable. Moreover, there was general agreement regarding
key variables in both databases and others studies, for example
regarding the sex-ratio, age distribution, andMS type (21, 22, 29),
which—overall—is reassuring. Lastly, the comparison between
1986 and 2016 is interesting but should be regarded critically.
The studies were conducted using different study designs and
target populations, in different times, which will likely impact
the results. Especially in the tails of the age distributions,
uncertainty is higher.
The estimation framework yielded a precise prevalence
estimate for MS in Switzerland, but is not limited to the present
use-case. The framework was constructed to be applicable to
any chronic disease. The framework reduces the limitations
of reliance on single datasets but also mitigates some caveats
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FIGURE 3 | Comparison of the number of MS cases per 100,000 inhabitants per age group between 1986 and 2016. The numbers are stratified by sex with women in
plot (A) and men in plot (B). The gray bands are the result of smoother functions being applied to the data and do not represent confidence intervals of the estimates.
of estimation methods based on aggregation from multiple
sources. Moreover, the integration of the critical appraisal step
for results andmethods ensures the integration of different expert
perspectives which therefore lead to greater credibility of the
estimation results, provided that critical expert appraisals are
adequately reflected in the research report. The proposed Swiss
estimation framework complements the recently introduced
4-step American framework by the United States Multiple
Sclerosis Prevalence Workgroup for health care reimbursement
claims (3). While our framework is generally generic and not
specific to a certain type of data, options for independent
case ascertainment—a key strength of the U.S. approach—
are very limited. However, our framework easily can integrate
information from algorithm-driven MS case identification in
claims data as used by the U.S. study, thereby strengthening the
evidence base.
We conclude that the number of persons diagnosed with MS
in Switzerland increased considerably in the last 30 years and
this increase could mainly be seen in women below the age of
65. Moreover, the use case demonstrates that the introduced
estimation framework is well-applicable in the context of
multiple sclerosis and helped to overcome common limitations
of health insurance data or clinic-based estimations.
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